"In the U.S., we will work on. . . Physician Payment Sunshine Act. . . compliance."
Last night, Merck filed more of its merger proxy soliciting materials with the SEC -- and here's the key new informational nugget -- on its Global Human Health set of businesses:
. . . .Across Global Human Health, we set a goal to stop or delay 75% of the strategic projects, including the staffing and funding that accompany those projects, if those projects are not related to driving our business in 2009 or compliance. For example, in EMEAC, where 28 markets have already rolled out new commercial models (NCM), we will not implement NCM in any new markets until after the merger. In the U.S., we continue to work on our obligations under the Physician Payment Sunshine Act, which is an initiative related to compliance, and will delay the initiatives looking at the customization of promotional resources. . . .
How much "re-focusing" of prior initiatives is underway in Kenilworth? And when we we read about thos efforts? As soon as they are communicated internally, and are of a size that they become "material information for informing the coming-proxy vote", we should read about them in Schering-Plough's SEC filings.
In any event -- CEO Hassan will make additional disclosurers come Monday: He'll report how many shares were voted in favor of (or against; or abstained from voting on) his retention -- and the retention of Compensation Committee Chairman Hans Becherer, at the Annual Meeting. I'll live blog Schering-Plough's Annual Shareholders' Meeting (in Chicago, this year), starting at 8:30 AM EDT -- right here. Stay tuned.
No comments:
Post a Comment